Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
暂无分享,去创建一个
R. Mayer | C. Schiffer | J. Moore | E. Frei | B. Powell | C A Schiffer | B L Powell | E Frei | D T Berg | R J Mayer | G. Omura | R B Davis | P Schulman | G A Omura | J O Moore | O R McIntyre | R. Davis | O. Mcintyre | P. Schulman | D. Berg | O. R. Mcintyre | R. J. Mayer | R. Davis | E. Frei | J. Moore | Roger B. Davis
[1] D. S. Gordon,et al. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial. , 1984, Blood.
[2] R. Weiss,et al. Cytarabine and neurologic toxicity. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Gray,et al. PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIAL , 1986, The Lancet.
[4] R. Mayer,et al. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Cox. Regression Models and Life-Tables , 1972 .
[6] B. Shank,et al. T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. , 1992, Blood.
[7] R. Mayer,et al. Allogeneic transplantation versus intensive chemotherapy in first-remission acute leukemia: is there a "best choice"? , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. Nimer,et al. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[10] D. Hurd. Postremission therapy for the younger adult patient with acute myelogenous leukemia: defining a role for transplantation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Rosenthal,et al. The role of intensive postinduction chemotherapy in the management of patients with acute myelogenous leukemia. , 1982, Cancer treatment reports.
[12] D. Catovsky,et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[13] H. Kantarjian,et al. Early intensification and short‐term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia , 1986, Cancer.
[14] B. Clarkson,et al. Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation. , 1992, The New England journal of medicine.
[15] B. Löwenberg. Post-remission treatment of acute myelogenous leukemia. , 1995, The New England journal of medicine.
[16] H. Gralnick,et al. Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.
[17] Stephen L. George,et al. Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .
[18] S. Nimer,et al. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. , 1992, Blood.
[19] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[20] J. Bennett,et al. Long term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group (ECOG) experience. , 1991, Leukemia research.
[21] C. Bloomfield. Post-remission therapy in acute myeloid leukemia. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] H. Preisler,et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. , 1987, Blood.
[23] C. Bloomfield,et al. Long-term disease-free survival in acute nonlymphocytic leukemia. , 1981, Blood.
[24] R. Gale,et al. CHEMOTHERAPY VERSUS TRANSPLANTATION IN ACUTE LEUKAEMIA , 1989, British journal of haematology.
[25] J. Curtis,et al. The Heritable Nature of Clonal Characteristics in Acute Myeloblastic Leukemia , 1981 .
[26] Varying intensity of postremission therapy in acute myeloid leukemia. , 1992 .
[27] H. Skipper,et al. EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. , 1964, Cancer chemotherapy reports.
[28] T. Barbui,et al. Short‐term remission induction and consolidation therapy for adult acute myelogenous leukemia , 2006, Hematological oncology.
[29] R. Mayer,et al. Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. , 1987, Seminars in oncology.
[30] J. Armitage,et al. Diagnostic concurrence in the subclassification of adult acute leukemia using French‐American‐British criteria , 1982, Cancer.
[31] J. Fleiss. Statistical methods for rates and proportions , 1974 .
[32] R. Gale,et al. High dose cytarabine: a review. , 1988, Leukemia.
[33] M. Labopin,et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe : further evidence of the role of marrow purging by mafosfamide , 1991 .
[34] A. Rimm,et al. 1993 progress report from the International Bone Marrow Transplant Registry. Advisory Committee of the International Bone Marrow Transplant Registry. , 1993, Bone marrow transplantation.
[35] W. Grove. Statistical Methods for Rates and Proportions, 2nd ed , 1981 .
[36] B. Meisenberg. Treatment of acute myelogenous leukemia. , 1995, The New England journal of medicine.
[37] F. Cavalli,et al. ACUTE MYELOGENOUS LEUKAEMIA: MAINTENANCE CHEMOTHERAPY AFTER EARLY CONSOLIDATION TREATMENT DOES NOT PROLONG SURVIVAL , 1984, The Lancet.
[38] R. Mertelsmann,et al. Acute nonlymphoblastic leukemia. Prognostic factors in adults with long‐term follow‐up , 1982, Cancer.
[39] R. Priore,et al. Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] J. Fay,et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] R. Mayer,et al. The approach to the elderly patient with acute myeloid leukemia. , 1993, Hematology/oncology clinics of North America.
[42] A. Rimm,et al. Progress report from the International Bone Marrow Transplant Registry. , 1992, Bone marrow transplantation.
[43] R. Gelber,et al. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update , 1983 .
[44] H. Preisler. Failure of remission induction in acute myelocytic leukemia. , 1978, Medical and pediatric oncology.
[45] C. Spurr,et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. , 1968, Blood.
[46] G. Tricot,et al. The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia , 1987, British journal of haematology.
[48] D. Galton,et al. ACUTE MYELOID LEUKAEMIA: IS ‘CONSOLIDATION’THERAPY NECESSARY? , 1984, British journal of haematology.
[49] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[50] N. Ifrah,et al. Double intensive consolidation chemotherapy in adult acute myeloid leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. , 1981 .
[52] K. Rai,et al. Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B. , 1987, Seminars in oncology.
[53] C. Sultan,et al. Distribution of 250 Cases of Acute Myeloid Leukaemia (AML) according to the FAB Classification and Response to Therapy , 1981, British journal of haematology.
[54] P. Jacobs,et al. In adult acute nonlymphoblastic leukaemia extended maintenance chemotherapy has no benefit , 1984, American journal of hematology.
[55] W. Hiddemann,et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.